Objective
Delivery of Nucleic Acid Therapeutics to desired organs has become the current challenge of biotechnological applications. Advancements on the chemical synthesis or targeting ligands, formulation of complex lipid systems, and their bioassays are essential to establish new gene therapies. Therefore, the main aim of NATPRIME DN is to establish a multidisciplinary training network on the emerging topic of nanoparticle-based adjuvants to deliver nucleic acid therapeutics (NAT). In the last decade, great efforts have been spent on the development of synthetic strategies for the creation of RNA based therapies/vaccines, and these efforts have been acknowledged by the Nobel committee in 2023. The next important step is targeted delivery, which is to carry NATs to the desired tissue. For this purpose, various nanoassemblies, i.e lipid nanoparticles, polyplexes, liposomes, that are modified with targeting ligands will be utilised to encapsulate NATS. Antibodies, peptides, glycans, and glycopolymers open up greater possibilities in the precise targeting of nanoparticles to desired organs/tissues/cells. The combined molecular toolbox of targeting ligands, charged lipids, helper lipids and PEG-replacement lipids need a high-throughput formulation-screening to ensure increased uptake of such particles in the desired organs. 15 interdisciplinary researchers will be trained on the design, synthesis, and characterisation of such complex targeting ligands, their formulation in nanoparticles, and their utilisation in the nucleic acid based treatments. Last but not least, biophysical understanding of molecular interactions of formulation components will bridge the gap between fundamental and applied research while broadening the horizon of ESRs from an academic lab to good manufacturing practice (GMP) synthesis facilities that can positively impact the well-being of future generations.
Fields of science
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- engineering and technologynanotechnologynano-materials
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
5612 AE Eindhoven
Netherlands
See on map
Participants (8)
3600 Frederikssund
See on map
9000 Gent
See on map
46012 Valencia
See on map
33000 Bordeaux
See on map
80539 Munchen
See on map
34906 Istanbul
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
151 85 Sodertaelje
See on map
79098 Freiburg
See on map
Partners (7)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
34342 Istanbul
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
80539 MUNCHEN
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1165 Kobenhavn
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3400 Klosterneuburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SW7 2AZ LONDON
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
G1 1XQ Glasgow
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CV4 8UW COVENTRY
See on map